has launched oral in , making it the first oral GLP-1 receptor agonist for obesity available in the country. General manager Paula Barriga confirmed the rollout on 3 November 2026, following approval from the in July.
The prescription-only treatment costs 236.20 euros for 30 tablets and lacks public funding. Indicated for adults with a BMI of 30 or above, or 27 with comorbidities, the daily pill achieved 16.6% average weight loss in a 64-week clinical study of 307 adults.
Spain is the fifth global market to offer the oral format, which requires no refrigeration. With 55% of Spanish adults currently overweight, Novo remains in talks with the regarding future state funding for the weight management drug.